ATE321069T1 - Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) - Google Patents

Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)

Info

Publication number
ATE321069T1
ATE321069T1 AT01943357T AT01943357T ATE321069T1 AT E321069 T1 ATE321069 T1 AT E321069T1 AT 01943357 T AT01943357 T AT 01943357T AT 01943357 T AT01943357 T AT 01943357T AT E321069 T1 ATE321069 T1 AT E321069T1
Authority
AT
Austria
Prior art keywords
pathological
growth factor
arteriogenesis
pigf
vascular
Prior art date
Application number
AT01943357T
Other languages
English (en)
Inventor
Peter Carmeliet
Desire Collen
Falco Sandro De
Ruvo Menotti
Original Assignee
Vlaams Interuniv Inst Biotech
D Collen Res Foundation Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE321069(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vlaams Interuniv Inst Biotech, D Collen Res Foundation Vzw filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE321069T1 publication Critical patent/ATE321069T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01943357T 2000-05-12 2001-05-10 Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) ATE321069T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00201714 2000-05-12

Publications (1)

Publication Number Publication Date
ATE321069T1 true ATE321069T1 (de) 2006-04-15

Family

ID=8171493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01943357T ATE321069T1 (de) 2000-05-12 2001-05-10 Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)

Country Status (10)

Country Link
US (8) US7482004B2 (de)
EP (1) EP1297016B1 (de)
AT (1) ATE321069T1 (de)
AU (2) AU2001265953B2 (de)
CA (1) CA2407858C (de)
DE (1) DE60118186T2 (de)
DK (1) DK1297016T3 (de)
ES (1) ES2260234T3 (de)
PT (1) PT1297016E (de)
WO (1) WO2001085796A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260234T3 (es) * 2000-05-12 2006-11-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Utilizacion de inhibidores del factor de crecimiento placentario para el tratamiento de la angiogenesis patologica, de la arteriogenesis patologica, de la inflamacion, de la formacion tumoral y/o de la perdida vascular.
US7273751B2 (en) * 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
GB2374870A (en) * 2001-01-26 2002-10-30 Thromb X Nv Use of genetically modified multicellular animals in the identification of drug target proteins
DE60236646D1 (de) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
AU2002252631A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
GB2384706A (en) * 2002-02-04 2003-08-06 Thromb X Nv Agent for the prevention or minimisation of post-operative adhesion formation and/or cell implantation
ITRM20020277A1 (it) * 2002-05-17 2003-11-17 Geymonat Spa Muteine del fattore di crescita placentare tipo 1, metodo di preparazione e loro applicazioni.
AU2003251729A1 (en) 2002-06-28 2004-01-19 K.U.Leuven Research & Development Use of antibodies against flt-1 for the treatment of osteoporosis
DE50309809D1 (de) 2002-11-16 2008-06-19 Dade Behring Marburg Gmbh Scd40l, papp-a und plazentaler-wachstumsfaktor (pigf) als biochemische markerkombinationen bei kardiovaskulären erkrankungen
GB0228409D0 (en) * 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
JP2007528355A (ja) * 2003-03-07 2007-10-11 アンジェスＭｇ株式会社 血管壁の炎症および新生内膜過形成を阻害する組成物および方法
CA2536321A1 (en) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
JP4503022B2 (ja) 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US7598043B2 (en) * 2004-11-19 2009-10-06 Cornell Research Foundation, Inc. Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
MX2007011735A (es) 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
US7867490B2 (en) 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications
CN101534865A (zh) * 2005-10-19 2009-09-16 Ibc药品公司 生物活性装配体的制备方法及其用途
CN100355882C (zh) * 2005-12-05 2007-12-19 中国人民解放军军事医学科学院放射与辐射医学研究所 杂交瘤细胞株及其产生的抗人vegfr－3的单克隆抗体
CA2669260C (en) * 2006-11-09 2019-01-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
AU2014200453B2 (en) * 2006-11-09 2015-06-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential gene expression in physiological and pathological angiogenesis
EP3293269A1 (de) * 2007-08-03 2018-03-14 MUSC Foundation For Research Development Menschliche monoklonale antikörper und verfahren zu ihrer herstellung
US8835183B2 (en) 2008-01-07 2014-09-16 Ortho-Clinical Diagnostics, Inc. Determination of sFlt-1:angiogenic factor complex
WO2009117791A2 (en) 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Mucosal gene signatures
CN102239178B (zh) 2008-10-02 2017-06-23 Vib研究所 抑制PlGF以治疗费城染色体阳性白血病
GB0914318D0 (en) 2009-08-14 2009-09-30 Medical Res Council Method
DE102010013555A1 (de) 2010-03-31 2011-10-06 Christian Hamm Verwendung der Biomarker sFlt und PIGF in der Diagnose und Therapie der pulmonalen Hypertonie
US9255927B2 (en) 2011-05-05 2016-02-09 Duke University Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics
ES2628321T3 (es) 2011-12-01 2017-08-02 Thrombogenics N.V. Mejora del resultado de una trabeculectomía
DK2838918T3 (da) 2012-04-20 2019-08-12 Merus Nv Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
JP2019507746A (ja) 2016-03-10 2019-03-22 オクシュリオン エヌブイ 胎盤増殖因子のアンタゴナイズによる後眼部線維症の阻害
WO2017201166A1 (en) * 2016-05-17 2017-11-23 Duke University Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer
EP3474859B1 (de) 2016-06-22 2025-12-24 Harless, William Warren Behandlung von krebs mit einem anti-krebs-stammzellenmittel in kombination mit einem neulsialidase-hemmer nach primärer krebstherapie
EP3849582B1 (de) * 2018-09-11 2025-12-31 Anbition S.r.l. Peptide und medizinische verwendungen davon
WO2020053773A1 (en) * 2018-09-11 2020-03-19 Anbition S.R.L. Peptides and medical uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
IT1242149B (it) * 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US20010021382A1 (en) * 1991-03-29 2001-09-13 Genentech, Inc. Vascular endothelial cell growth factor antagonists
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US6846839B1 (en) * 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
GB9723780D0 (en) * 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
ES2389387T3 (es) * 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
WO1999060846A1 (en) 1998-05-26 1999-12-02 Innogenetics N.V. Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
WO2001057067A1 (en) * 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
ES2260234T3 (es) * 2000-05-12 2006-11-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Utilizacion de inhibidores del factor de crecimiento placentario para el tratamiento de la angiogenesis patologica, de la arteriogenesis patologica, de la inflamacion, de la formacion tumoral y/o de la perdida vascular.
AU2003251729A1 (en) * 2002-06-28 2004-01-19 K.U.Leuven Research & Development Use of antibodies against flt-1 for the treatment of osteoporosis
MX2007011735A (es) * 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.
US7867490B2 (en) * 2005-06-30 2011-01-11 Vib Vzw Treatment of liver cirrhosis and its complications

Also Published As

Publication number Publication date
US20090238826A1 (en) 2009-09-24
DE60118186D1 (de) 2006-05-11
US20130177564A1 (en) 2013-07-11
US20130183310A1 (en) 2013-07-18
DK1297016T3 (da) 2006-07-10
WO2001085796A2 (en) 2001-11-15
EP1297016A2 (de) 2003-04-02
US7482004B2 (en) 2009-01-27
CA2407858A1 (en) 2001-11-15
EP1297016B1 (de) 2006-03-22
AU6595301A (en) 2001-11-20
DE60118186T2 (de) 2006-12-28
AU2001265953B2 (en) 2005-09-29
US20090162354A1 (en) 2009-06-25
US20090074765A1 (en) 2009-03-19
US20130177565A1 (en) 2013-07-11
PT1297016E (pt) 2006-07-31
CA2407858C (en) 2015-10-27
WO2001085796A3 (en) 2002-04-04
ES2260234T3 (es) 2006-11-01
US20120263710A1 (en) 2012-10-18
US20030180286A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
DE60118186D1 (de) Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
MA58373B1 (fr) Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
ATE368662T1 (de) Piperidinyl-thiazol-carbonsäure-derivate als angiogenesis inhibitoren
ATE328612T1 (de) Therapeutische zusammensetzungen zur behandlung von schleimhypersekretion
ATE319465T1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
MXPA03006806A (es) Metodo para usar variante del receptor del factor de crecimiento celular endotelial vascular para tratar psoriasis y para mejorar curacion de heridas.
ATE399203T1 (de) Varianten des wachstumsfaktors der vaskulären endothelzellen, ihre verwendung sowie methoden für ihre herstellung
SE9800836D0 (sv) New Compounds
DE60226154D1 (de) Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
EP1259235A4 (de) Tyrosinkinase inhibitoren
MX2022016237A (es) Proteinas actrii para el tratamiento de la hipertension arterial pulmonar (hap).
ATE446514T1 (de) VERWENDUNG VON ßHYPOXIA INDUCIBLE FACTOR 2ALPHAß ZUR BEHANDLUNG VON ßNEONATAL RESPIRATORY DISTRESS SYNDROMEß
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
ATE403433T1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
ATE345788T1 (de) Verwendung von mek hemmern zur behandlung von virusvermitteltem hämorragischem schock oder fieber
ATE334693T1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
DE60313803D1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
BG105953A (bg) Метод за лечение на хронична обструктивна белодробна болест
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE60119285D1 (de) Verwendung von plgf zur vorbeugung oder behandlung von ischaemie oder schlaganfall

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1297016

Country of ref document: EP